Sanofi-Aventis looks to Acomplia for heart disease treatment

11/16/2004 | NYTimes.com

The company said its drug, already touted for fighting obesity and smoking, has shown promise in improving cholesterol and other heart disease factors, and a Sanofi-Aventis vice president said the company will soon start studies in those areas. Dr. Douglas Greene also outlined the first details of Acomplia's safety and side effects, including a doubled risk of depression.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA